Since SPLUNC1 fails to regulate ENaC in the CF lung (Fig. 1b) [21], Spyryx Biosciences is currently developing a SPLUNC1-derived peptide, which functions in CF airways as an ENaC inhibitor (Fig. 1c) [18, 59]. The gene discussed is BPIFA1; the disease is cystic fibrosis.